BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 6151691)

  • 1. Mechanisms of acquired immunity in leishmaniasis.
    Howard JG; Liew FY
    Philos Trans R Soc Lond B Biol Sci; 1984 Nov; 307(1131):87-98. PubMed ID: 6151691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY; Howard JG; Hale C
    J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY; Singleton A; Cillari E; Howard JG
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P; Pearce E; Natovitz P; Sher A
    J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological regulation of experimental cutaneous leishmaniasis. III. Nature and significance of specific suppression of cell-mediated immunity in mice highly susceptible to Leishmania tropica.
    Howard JG; Hale C; Liew FY
    J Exp Med; 1980 Sep; 152(3):594-607. PubMed ID: 6447751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes.
    Howard JG; Liew FY; Hale C; Nicklin S
    J Immunol; 1984 Jan; 132(1):450-5. PubMed ID: 6197456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection.
    Howard JG; Nicklin S; Hale C; Liew FY
    J Immunol; 1982 Nov; 129(5):2206-12. PubMed ID: 7119442
    [No Abstract]   [Full Text] [Related]  

  • 9. Murine cutaneous leishmaniasis: disease patterns in intact and nude mice of various genotypes and examination of some differences between normal and infected macrophages.
    Handman E; Ceredig R; Mitchell GF
    Aust J Exp Biol Med Sci; 1979 Feb; 57(1):9-29. PubMed ID: 314286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity.
    Saha B; Das G; Vohra H; Ganguly NK; Mishra GC
    Eur J Immunol; 1995 Sep; 25(9):2492-8. PubMed ID: 7589116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells.
    Liew FY; Hale C; Howard JG
    J Immunol; 1982 Apr; 128(4):1917-22. PubMed ID: 6120976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica.
    Howard JG; Hale C; Liew FY
    J Exp Med; 1981 Mar; 153(3):557-68. PubMed ID: 6454739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity.
    Titus RG; Lima GC; Engers HD; Louis JA
    J Immunol; 1984 Sep; 133(3):1594-600. PubMed ID: 6205088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the host response to Leishmania mexicana.
    Pérez H
    Ciba Found Symp; 1983; 99():157-73. PubMed ID: 6227462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY; Dhaliwal JS
    J Immunol; 1987 Jun; 138(12):4450-6. PubMed ID: 3295049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.